Fred B. Davenport, Former PPD, Inc. (PPDI) President, Joins Clinipace Worldwide Board Of Directors

Clinipace Worldwide a global, digital clinical research organization (dCRO), today announced the addition of industry veteran Fred B. Davenport, Jr., to its Board of Directors.

As an independent director, Fred brings to Clinipace a significant pedigree in scaling global organizations within the CRO industry, having spent 10 years at Pharmaceutical Product Development, Inc. (PPD) during its rapid growth phase, followed by 6 years on the Board of Directors for Medpace, Inc. At PPD, Fred served in various roles, including General Counsel, Executive Vice President, and President.

Suggested Articles

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.

In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.